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ABSTRACT  
BACKGROUND & AIMS: Patients with bi-allelic germline mutations in mismatch repair 
(MMR) genes (MLH1, MSH2, MSH6, or PMS2) develop a rare but severe variant of Lynch 
syndrome called constitutional MMR deficiency (CMMRD). This syndrome is characterized 
by early-onset colorectal cancers, lymphomas or leukemias, and brain tumors. There is no 
satisfactory method for diagnosis of CMMRD because screens for mutations in MMR genes 
are non-informative for 30% of patients. MMR-deficient cancer cells are resistant to 
genotoxic agents and have microsatellite instability (MSI), due to accumulation of errors in 
repetitive DNA sequences. We investigated whether these features could be used to 
identify patients with CMMRD.  
 
METHODS: We examined MSI by PCR analysis and tolerance to methylating or thiopurine 
agents (functional characteristics of MMR-deficient tumor cells) in lymphoblastoid cells 
(LCs) from 3 patients with CMMRD and 5 individuals with MMR-proficient LCs (controls). 
Using these assays, we defined experimental parameters that allowed discrimination of a 
series of 14 patients with CMMRD from 52 controls (training set). We then used the same 
parameters to assess 23 patients with clinical but not genetic features of CMMRD.  
 
RESULTS: In the training set, we identified parameters, based on MSI and LC tolerance to 
methylation, that detected patients with CMMRD vs controls with 100% sensitivity and 
100%. Among 23 patients suspected of having CMMRD, 6 had MSI and LC tolerance to 
methylation (CMMRD highly probable), 15 had neither MSI nor LC tolerance to methylation 
(unlikely to have CMMRD), and 2 were considered doubtful for CMMRD based on having 
only 1 of the 2 features. 
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CONCLUSION: The presence of MSI and tolerance to methylation in LCs identified patients 
with CMMRD with 100% sensitivity and specificity. These features could be used in 
diagnosis of patients. 
 
KEYWORDS: functional tests, colon cancer, tumor, predisposition 
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INTRODUCTION 
Individuals with Lynch syndrome (LS) harbor germline heterozygous mutations affecting 
one of the four major mismatch repair (MMR) genes (i.e. MLH1, MSH2, MSH6 or PMS2) 
and are at greatly increased risk of developing colorectal and other epithelial tumors 1. 
Typically, individuals with germline MLH1 or MSH2 defects develop MMR-deficient cancers 
during their 4th or 5th decade, whereas those with MSH6 or PMS2 mutations are affected 
less consistently. Patients with bi-allelic germline mutations in MMR genes suffer from 
Constitutional MMR-Deficiency (CMMRD) 2-5, a distinct inherited cancer syndrome (OMIM 
#276300) 6. This syndrome is characterized by the development of childhood tumors such 
as early-onset colorectal cancers, lymphomas/leukemias, and brain tumors 6-8. Since 
CMMRD is mainly due to bi-allelic inheritance of PMS2 or MSH6 germline mutations, the 
family history of patients shows only a low incidence of LS-related cancers in first- and 
second-degree relatives. To date, CMMRD has been reported in 146 patients from 91 
distinct families. Because of variable clinical presentation, lack of unequivocal diagnostic 
features, and phenotypical overlap with other cancer syndromes (e.g. neurofibromatosis 
type 1 (NF1), Li-Fraumeni, syndrome, familial adenomatous polyposis (FAP)), CMMRD 
syndrome is frequently unrecognized by clinicians and its incidence is almost certainly 
underestimated.  
Within the European Consortium ‘Care for CMMRD’ (C4CMMRD), we recently proposed 
clinical diagnostic criteria that should raise the suspicion of CMMRD when observed in a 
child or young adult cancer patient, based on the phenotypic presentation 9. The suspected 
diagnosis then needs to be either confirmed or refuted. The current diagnosis of CMMRD 
requires identification of bi-allelic, deleterious germline MMR defects. Unfortunately, 
mutation analysis leads to non-informative results when variants of unknown functional 
significance (VUS) are detected, as observed in around 30% of patients. Moreover, the 
detection of PMS2 alterations responsible for 60% of CMMRD families is complicated by 
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the presence of numerous pseudogenes, resulting in a lack of sensitivity when performing 
mutation analysis only. Hence, although extensive mutation screening that includes 
comprehensive searches for large genomic rearrangements of MMR genes remains crucial 
for identification of CMMRD patients and genetic counseling in CMMRD families, tests that 
can unequivocally confirm or refute a suspected diagnosis are highly desirable. 
Since all CMMRD patients share a common and specific functional property, i.e. MMR 
deficiency, we hypothesized that the detection of characteristic functional features of MMR-
deficient blood cells from such patients could be used to diagnose this syndrome. 
Inactivation of MMR is known to increase cellular tolerance to specific genotoxic agents 
such as methylating and thiopurine drugs 10-15. Moreover, MMR-deficient cancer cells 
specifically exhibit a microsatellite instability (MSI) phenotype due to accumulation of 
replication errors in repetitive DNA sequences 16. In tissues derived from MMR-deficient 
neoplastic cells, MSI is easily detected through PCR amplification of microsatellites. 
However, earlier studies have shown that MSI cannot be detected in the germline DNA of 
CMMRD patients except by using the laborious technique of “small pool PCR” 6, 17. The 
presence of somatic mutations within DNA repeats in MMR-deficient cells is related to cell 
division. We therefore hypothesized that in vitro culture of immortalized lymphoblastoid cells 
from CMMRD patients would eventually lead to the onset of both an MSI phenotype and 
tolerance to methylating/thiopurine agents.  
In the present work we first validated the proof of concept that MSI and tolerance to 
methylating/thiopurine agents could be detected in lymphoblastoid cell lines (LCLs) derived 
from several CMMRD patients, but not in LCLs from MMR-proficient controls including LS 
patients. In a case-control study, we next determined the experimental conditions that 
allowed accurate discrimination of a series of CMMRD patients from MMR-proficient 
controls. Finally, we tested our functional approach using the same experimental conditions 
in a series of patients who showed clinical characteristics of CMMRD but for whom the 
standard diagnostic method was non-informative. This was performed within a European 
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Consortium ‘Care for CMMRD’ (C4CMMRD) that allowed us to collect a unique series of 
confirmed CMMRD cases and at-risk individuals for this syndrome. 
PATIENTS AND METHODS 
Patients 
At the 1st workshop of the European Consortium ‘Care for CMMRD’ (C4CMMRD) held in 
Paris on June 9, 2013, a call was made to contribute blood samples or LCLs from definite 
or possible CMMRD patients. Eligible subjects included patients already diagnosed with 
CMMRD, i.e. with bi-allelic deleterious germline mutations in any of the 4 major MMR 
genes, as well as patients with a strong clinical suspicion of CMMRD, i.e. with a clinical 
score ≥3 according to Wimmer et al. 9. LCLs were available (n=10) or were established 
(n=27) for 37 of the 42 eligible patients. MMR-proficient LCLs used as controls originated 
from 47 LS patients and 15 subjects considered free of MMR germline defects including 
patients with FAP or NF1 syndrome. All patients gave written informed consent. This study 
was approved by the institutional review boards/ethics committees of the participating 
centres. 
Mutation screening of MMR genes 
All analyses were performed in clinically approved laboratories. Analysis of MLH1, MSH2 
and MSH6 genes was performed across different laboratories whereas analysis of PMS2 
was performed in the Rouen, Lille or Innsbruck laboratories. Bi-directional Sanger 
sequencing from genomic DNA or direct cDNA sequencing 18 was performed to identify 
point mutations in exonic and flanking intronic regions. Sequencing reactions were 
performed using the ABI PRISM Kit (Applied Biosystems) and sequences were analyzed on 
an automated sequencer (ABI 3130XL Genetic Analyzer, Applied Biosystems) using 
Sequencing Analysis Software v5.2 (Applied Biosystems) 19. Screening for large 
rearrangements in the MLH1, MSH2 and MSH6 genes was performed using Multiplex 
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Ligation-dependent Probe Amplification and/or Quantitative Multiplex PCR of Short 
Fluorescent Fragments. Rearrangements of the PMS2 gene were analyzed by Quantitative 
Multiplex PCR of Short Fluorescent Fragments for exons 6, 7, 8 and 10, and/or by Multiplex 
Ligation-dependent Probe Amplification using the SALSA MLPA kit P008 (MRC-Holland, 
Amsterdam, The Netherlands) together with appropriate reference DNAs that have an 
equal (2:2) distribution of gene- and pseudogene-derived sequences in exons 13-15 20. In 
patient C26, the PMS2-exon 12 deletion escaped detection by Multiplex Ligation-dependent 
Probe Amplification, but was identified by direct cDNA sequencing. Screening of the NF1 
gene was performed using a variety of methodologies including DNA and RNA sequencing 
for small lesions, polymorphic microsatellite marker analysis and Multiplex Ligation-
dependent Probe Amplification or real-time PCR-based gene dosage analysis to allow the 
assessment of microdeletions, as previously described 21. Mutation analysis of the APC 
gene was performed by direct sequencing and Multiplex Ligation-dependent Probe 
Amplification 22. 
Lymphoblastoid cell lines  
LCLs obtained following standard Epstein-Barr virus infection were grown in RPMI 1640 
with stable glutamine supplemented with 20% fetal calf serum, 100 IU/ml penicillin and 
100mg/ml streptomycin (PAA). Only LCLs with comparable growth rates and with viability 
greater than 85% were included.  
Ex vivo microsatellite instability analysis 
PCR products following amplification of the NR27, NR21 and BAT26 microsatellites were 
separated by capillary electrophoresis on an ABI 3100 genetic analyzer and quantified 
using Gene Mapper software v3.7. In order to confidently detect allelic shifts of as little as 1 
base pair in size, DNA from LCL and peripheral blood lymphocytes (PBLs) were analyzed 
concurrently in octuplicate.  
Chemicals  
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All chemicals were obtained from Sigma unless otherwise indicated. Cells were exposed to 
6-Thioguanine (6-TG) and N-Methyl-N'-Nitro-N-Nitrosoguanidine (MNNG) (TCI Europe). To 
exclude differences in MNNG cytotoxicity due to variations in O6-methylguanine 
methyltransferase enzyme activity, the latter was abrogated by exposure to O6-
benzylguanine (20µM final concentration) during the entire experiment. All chemicals were 
dissolved in DMSO to a concentration of 20mM, protected from light and stored at -20°C 
until used. 
Methylation tolerance assay 
Exponentially growing lymphoblastoid cells were seeded into 96-well round-bottom plates at 
a density of 0.15-1×104 cells/well. After 24-h incubation, extemporaneously reconstituted 
MNNG solution was added at 1.25, 2.5 and 5µM final concentration. Because of the short 
half-life of MNNG in aqueous solution (1 hour), the medium was not replaced after drug 
treatment and 1, 2 or 3 rounds of treatment separated by 24-h were performed. Cell growth 
was evaluated after a total incubation time of 10 days and all samples were tested in 
triplicate. Each experiment was conducted at least in duplicate. Cytotoxicity was examined 
by the WST kit according to the supplier’s recommendations (Roche). Absorbance was 
read at 450nm using a microplate reader (Tecan Infinite F500) and analyzed using 
Xfluor4GENiosPro software. Percent cell survival was represented as the absorbance of 
treated sample relative to control.  
Statistical analyses 
A Metropolis-Hastings algorithm was used to estimate the sensitivity and specificity of the 
three different diagnostic methods (MMR gene sequencing, functional testing, gMSI 
testing). This algorithm was applied to results obtained from genetically confirmed CMMRD 
patients, control patients, and patients with a strong clinical suspicion of CMMRD but 
without a molecularly confirmed diagnosis. 
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Further information is available in the Supplementary material. 
 
RESULTS 
Proof-of-concept study  
We first investigated whether MSI and methylation/thiopurine tolerance could be detected in 
LCLs from 3 CMMRD patients with bi-allelic deleterious mutations in MSH6, PMS2 or 
MLH1, but not in LCLs from 5 negative controls comprising 4 LS patients (MSH6, MSH2, 
PMS2 or MLH1 heterozygous mutations) and one individual with wild-type MMR status.  
MSI screening. As expected, MSI was not detected in PBLs from CMMRD patients (figure 
1A) following the analysis of 3 mononucleotide microsatellite markers (NR27, NR21, 
BAT26) that are used routinely to assess MSI status in tumor cells. In contrast, a clear MSI 
phenotype showing characteristic, aberrant alleles was observed in LCLs from all 3 
CMMRD patients (figure 1A), whereas the 5 control LCLs displayed stable allelic profiles 
(figure 1B and supplementary table 2). The MSI phenotype was only demonstrated ex vivo 
in LCLs and was thus termed evMSI to distinguish it from the in vivo MSI phenotype 
detected in MMR-deficient cancer cells.  
Drug tolerance assay. We first evaluated the cytotoxic effects of MNNG (methylating 
agent) and 6-thioguanine (6-TG, thiopurine) in 11 human colorectal cancer cell lines. Cell 
lines that were MLH1-, MSH2- or MSH6-deficient were on average up to 10-fold more 
tolerant to 1µM MNNG than MMR-proficient cell lines and 2-fold more tolerant to 15µM 6-
TG (supplementary figure 1). We next investigated the response of LCLs to both drugs. All 
3 CMMRD-derived LCLs were phenotypically distinguishable from cells with heterozygous 
or wild-type MMR status. They displayed better cell survival compared to controls and there 
was no overlap between the two groups under several MNNG experimental conditions 
(figure 1C), whereas 6-TG was less discriminant (figure 1D).  
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Case-control study 
We next sought to identify experimental conditions that would best discriminate CMMRD 
patients from controls. Among 42 patients collected from several European cancer centers 
(including the 3 patients previously analyzed in the proof of concept study), 19 had been 
diagnosed as definite CMMRD cases by molecular analysis, i.e. bi-allelic pathogenic MMR 
gene alterations. Of these, LCLs from 14 cases were available for the present case-control 
study (table 1, figure 2). Pedigrees for all previously unreported patients are shown in 
supplementary figure 2. Clinical and tumor data together with detailed results of germline 
MMR analysis are provided in supplementary table 1. 
evMSI. LCLs from the 14 CMMRD patients comprising carriers of bi-allelic mutations in 
PMS2 (n=10), MSH6 (n=3) or MLH1 (n=1) displayed microsatellite deletions ranging from 1 
to 7 base pairs (figure 4A). Detection of the evMSI phenotype in the cell lines was achieved 
120 days after immortalization at the latest. The median culture time for a positive evMSI 
phenotype was 83.6 ± 22.6 days (range 45-120) (supplementary table 2). In contrast, LCLs 
from all 23 MMR-proficient controls (12 LS patients and 11 MMR wild-type individuals) 
showed no deletions. For all 23 controls except two, the cell lines were grown for at least 
120 days without any evidence of deletions (median culture time = 175 days ± 62.6, range 
83-304 days). Five control cell lines were grown for longer than 220 days without any 
evidence of deletions. Therefore, for subsequent experiments the cut-off value used to 
define a cell line as positive for evMSI was set as a 1 base pair deletion across all three 
markers and a maximum culture time of 120 days was used. 
Drug tolerance assays. By varying the MNNG concentration and number of treatments, 
we found the optimal experimental condition that allowed CMMRD patients to be 
discriminated from controls was two rounds of 2.5 µM MNNG. Using this condition, LCLs 
from all 14 CMMRD patients displayed a cell survival rate above 60%. In contrast, 51/52 
LCLs from controls displayed a cell survival rate lower than 40% (median cell survival rates 
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of 87.5% and 20.9%, respectively; < .0001; Student’s t test) (figures 3 and 4A). At an 
arbitrary cut-off value of 50% cell survival, the methylation tolerance assay was therefore 
shown to be 100% sensitive (14/14) and 98% specific (51/52; the positive sample was from 
an LS patient with an MSH6 defect). The thiopurine tolerance test was found to be less 
discriminatory and hence was not continued further (supplementary figure 3). This result 
concurs with previous findings that MMR-deficient cells are 100-fold more tolerant than 
MMR-proficient cells to death induced by methylating agents, but only about 10-fold more 
tolerant to 6-TG treatment 23. 
Overall, evMSI and methylation tolerance assays were found to be highly specific and 
sensitive and gave concordant results for all cases tested with both methods. In subsequent 
studies we therefore deemed that both assays must show abnormal results in order to 
conclude a definite diagnosis of CMMRD. To rule out a diagnosis of CMMRD, both assays 
should display normal results. Diagnosis should be considered as doubtful if results from 
the two functional tests are discordant. 
Application of functional tests for the detection of CMMRD in at-risk 
individuals  
In 23 of the 42 patients from our series, a diagnosis of CMMRD was suspected based on 
clinical presentation, but the diagnosis could not be confirmed by MMR gene mutation 
analysis (table 1, figure 2). These comprised 8 patients with bi-allelic MMR mutations that 
included one or two VUS, 5 patients with a single MMR mutation and 10 patients in which 
no MMR mutation was detected. We evaluated these patients using the functional assay 
conditions described above (table 2, figure 4B). Six patients displayed positive results for 
both the evMSI and methylation tolerance assays, indicating a highly probable diagnosis of 
CMMRD. They included 5 patients with MSH6 or PMS2 bi-allelic MMR alterations 
comprising VUS. Consistent with our results, in silico prediction favored a pathogenic 
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nature for the MSH6 and PMS2 variants in four of these patients (C20.1, C20.2, C18, C22). 
In the 6th patient (C29.1), no apparent germline MMR mutations were detected. In another 
15 patients, evMSI and methylation tolerance assays were both negative, indicating that a 
diagnosis of CMMRD was very unlikely. These included one compound heterozygote for an 
MSH2 variant, 5 patients with a single MLH1, PMS2 or MSH2 alteration, and 9 patients 
where no MMR alteration had been detected. In the two remaining patients (C21 and C23, 
with bi-allelic MSH6 mutations comprising one or two VUS, respectively), the data showed 
methylation tolerance but no evMSI phenotype. We therefore concluded a result of 
“doubtful” for both patients.  
Comparison of functional assays with other methodological approaches  
We trialed a recently described method that evaluates dinucleotide repeats for the detection 
of MSI in germline DNA (gMSI) 24. In the case-control cohort, the gMSI assay yielded 
interpretable results in 15 of 18 CMMRD patients and in 16 of 19 controls. CMMRD patients 
with bi-allelic mutations involving PMS2 (n=11), MLH1 (n=1) or MSH2 (n=1) displayed 
abnormal gMSI values. In agreement with the original report 24, we found however that 
CMMRD patients with bi-allelic deleterious mutations involving MSH6 (n=2) displayed 
normal gMSI ratios, thus reducing the sensitivity of this method (table 2, supplementary 
table 3, supplementary figure 4). gMSI ratios were normal for all controls. gMSI also yielded 
interpretable results in 21 of 23 patients suspected of having CMMRD. The five carriers of 
bi-allelic MSH6 alterations displayed normal gMSI, as expected. Moreover, gMSI 
corroborated the results of our functional assays in all patients with PMS2, MLH1 or MSH2 
mutations, with the exception of one (C18). This patient carried one deleterious mutation 
and one VUS in the PMS2 gene. He displayed normal gMSI but abnormal evMSI and 
methylation tolerance results (table 2). The c.2249G>A missense mutation found in the 
PMS2 gene of patient C18, together with complete deletion of the other PMS2 allele, was 
previously reported in a patient diagnosed with rectal cancer and a brain tumor at 22 and 23 
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years of age, respectively 25. This further corroborates a pathogenic role for the VUS in 
patient C18 and is consistent with the results of our functional assay. The evMSI, 
methylation tolerance and gMSI assay results were all abnormal in patient C29.1 who 
lacked apparent MMR germline mutations. This prompted us to conduct additional PMS2 
screening using Multiplex Ligation-dependent Probe Amplification, which led to the 
identification of a homozygous deletion of exons 14-15. Normal functional test results and 
gMSI ratio were found in an asymptomatic brother aged 11 years (C29.2) who was later 
found to be heterozygous for the PMS2 deletion.  
Another tool proposed for CMMRD screening is IHC analysis to detect loss of MMR 
protein expression in normal tissues. IHC was recently reported to be 100% sensitive when 
performed on normal colonic or skin tissues from 5 CMMRD patients 26. However, based on 
previous observations in LS patients, IHC may lack sensitivity, especially for the detection 
of some missense and truncating MMR gene mutations 27 , 28, resulting in false negative 
diagnosis for CMMRD. This was demonstrated in the present study where positive MSH6 
staining was observed in two patients (C20.2 and C22) with homozygous MSH6 missense 
mutations and who are likely to be CMMRD according to the functional assays and in silico 
predictions. Conversely, PMS2 protein was not expressed in the normal colonic mucosa of 
patient C25, the carrier of a single deleterious PMS2 mutation in which a diagnosis of 
CMMRD was ruled out based on normal results for the evMSI, methylation tolerance and 
gMSI tests (table 2 and supplementary table 1).  
Estimation of sensitivity, specificity, positive predictive value (PPV) and 
negative predictive value (NPV) for the functional assays and for other 
methodological approaches 
In our case-control cohort, the functional assay (i.e. evMSI and methylation tolerance) was 
100% sensitive and 100% specific whereas gMSI testing was 86.7% (13/15) sensitive and 
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100% (16/16) specific (see above). It is worth noting that the sensitivity of gMSI is likely to 
be an overestimate, since this depends on the proportion of CMMRD patients with MSH6 
alterations. In our series this was only 13% (2/15), however MSH6 alterations are thought to 
be responsible for a higher proportion (~20%) of all CMMRD patients 9. The performance of 
IHC could not be evaluated properly due to the lack of a standardized method for the 
analysis of MMR gene expression in the normal tissue of controls (i.e. MMR-proficient 
cases). 
We next estimated the performance of functional testing compared to the standard 
method of MMR gene sequencing. This was done for the entire cohort, including patients 
deemed to be at-risk. Using a Metropolis-Hastings algorithm, the functional assay revealed 
higher sensitivity (94.2% (95% CI: 79.4% - 99.9%) vs 80.1% (54.1% - 99.0%)), higher NPV 
(97.2% (89.8% - 99.9%) vs 91.2% (76.6% - 99.6%)), but lower specificity (90.1% (76.1% - 
99.5%) vs 97.6% (91.2% - 99.9%)) and lower PPV (80.5% (53.9% - 99%) vs 93.6% (77.9% 
- 99.8%)) for CMMRD diagnosis. In order to include gMSI in the comparison, an estimation 
of the sensitivity and specificity was made in the smaller series of patients and controls for 
which results from all tests were available. Functional testing still offered the highest 
sensitivity (93.3% (76.7% - 99.8%) and a lower specificity (Supplementary table 4), 
however these differences did not reach statistical significance because of small cohort 
sizes. As stated above, the lack of a standardized method for IHC analysis of normal 
tissues meant we were unable to properly evaluate the sensitivity and specificity of this 
method. 
DISCUSSION 
In this paper, we propose a new approach for the diagnosis of CMMRD that involves the 
common and specific functional characteristic of all CMMRD patients, i.e. MMR deficiency. 
Our approach was based on the exploitation of this feature through the evaluation of MSI 
and methylation tolerance in MMR-deficient, immortalized lymphoblastoid cells. This 
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method gave unequivocal results in CMMRD patients with known bi-allelic deleterious 
mutations. If one assumes that abnormal results for both assays indicate a diagnosis of 
CMMRD, whereas normal results for both assays rule this out, our method was 100% 
sensitive and 100% specific in this case-control study. When applied to additional patients 
suspected of having CMMRD syndrome because of evocative clinical criteria but who 
lacked the confirmatory standard genetic defects, a clear discrimination into two groups was 
obtained. In the first group showing abnormal results for both tests, we considered that 
CMMRD was highly probable. In contrast, a diagnosis of CMMRD was highly unlikely in the 
second group of patients showing normal results for both tests. Our novel functional 
approach may therefore be especially useful for the confirmation or rejection of CMMRD 
diagnosis in patients with VUS by providing an assessment of the pathogenicity of MMR 
variants. It is also useful in cases where the diagnostic method failed to detect bi-allelic 
MMR mutations despite an evocative CMMRD clinical phenotype (e.g. patient C29.1). 
Furthermore, our approach can rule out that a second mutation has been missed in patients 
with heterozygous, pathogenic PMS2 or MSH2 mutations who nevertheless show an 
unusually early onset of cancer (e.g. colon tumors at 12, 17 and 25 years of age in patients 
C24, C26 and C25, respectively). The results from our functional approach support the 
existence of a clinical continuum that spans the less severe CMMRD phenotypes that 
mimic LS (e.g. patient C18), to more severe and early onset LS phenotypes that mimic 
CMMRD 29. Overall, our findings highlight that functional tests capable of assessing 
constitutional MMR-deficiency are highly desirable for the accurate diagnosis of CMMRD 
patients.  
Although we have investigated by far the largest CMMRD series reported to date in the 
literature, our method requires further confirmation in additional cohorts of CMMRD 
patients. This will help to refine the criteria for the functional assays in cases with 
ambiguous results, such as the two patients who harbored VUS in the MSH6 gene and 
showed methylation tolerance but not evMSI (C21, C23). One possible explanation for this 
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observation is that certain MMR gene mutations might uncouple the DNA mismatch repair 
and DNA damage-induced apoptosis functions, as reported in mice 30, 31. Overall, we found 
that functional testing showed better sensitivity than either MMR gene sequencing or gMSI, 
although it may have a lower specificity. Bearing this in mind, we propose a flow chart for 
the use of our assay alone or in combination with other tests in routine clinics in the next 
future (figure 5). IHC could not be evaluated properly in this study due to the lack of a 
standardized method for assessment of MMR gene expression in the normal tissues of 
MMR-proficient subjects. The results with IHC are likely to be highly dependent on the type 
of tissue being studied (e.g. colon, brain, skin, lymphoid cells). Moreover, it is well known 
that IHC can give rise to false negative results for MMR deficiency in cases where 
inactivating missense mutations nevertheless result in expression of the mutant protein 27 , 
28
. Further studies should evaluate MMR protein expression using standardized methods in 
normal and tumor tissues from large cohorts of CMMRD patients, MMR-proficient controls 
and Lynch syndrome patients, in the same manner as performed here to assess our 
functional assay. 
 
In summary, the novel functional approach proposed here showed higher sensitivity for 
CMMRD diagnosis compared to MMR sequencing or gMSI, the two other methods used so 
far. This approach can be used to determine whether MMR variants of uncertain 
pathogenicity are responsible for functional inactivation of the MMR system. The ability to 
classify variants as pathogenic or neutral is a major challenge in clinical genetics, 
particularly with the advent of next-generation sequencing. Moreover, the diagnosis of 
CMMRD syndrome based solely on clinical and genetic data is presently inadequate. As an 
overall diagnostic strategy, we therefore recommend the implementation of our functional 
assays in combination with IHC and gMSI analysis (figure 5). These tests can be performed 
in any order upon suggestion of CMMRD syndrome based on an evocative clinical score. 
This strategy has already been introduced at the Saint-Antoine Hospital in Paris with the 
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aim of further validating our assay in an independent cohort of CMMRD patients. The 
service is available upon request. We are confident this assay will provide a functional 
definition, or “signature”, for CMMRD, similar to the chromosomal breakage test for 
diagnosis of Fanconi anemia. In the near future, we believe that individuals who are at-risk 
of CMMRD will be tested solely using functional assays as the initial test.  
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LEGENDS 
Figure 1. Proof of concept study. (A) LCLs but not PBLs from CMMRD patients display 
evMSI. Electrophoretograms of fluorescent amplification products for NR27, NR21 and 
BAT26 microsatellites. The length of the predominant allele in base pairs (bp) and the 
fluorescence intensity are indicated in the box below each profile. Deletions (red arrows) 
occurred at these loci in lymphoblastoid cell lines (LCLs) derived from CMMRD patients 
C01.1 (PMS2 deficient), C14 (MSH6 deficient) and C15 (MLH1 deficient) compared with 
their respective peripheral blood lymphocytes (PBLs). In PBLs, the PCR profiles were 
similar in CMMRD patients C01.1 or C14 and their respective parents, demonstrating that 
MSI could only be demonstrated ex vivo. (B). CMMRD patients but not controls display 
evMSI. Deletions, expressed as the size of deletion for each marker and the cumulative 
size of deletion (i.e. the sum of the deletions observed in the 3 markers) were observed in 
LCLs from the 3 CMMRD patients but not in MMR-proficient controls that included 4 LS 
patients and one individual with wild-type (wt) MMR status. (C) LCLs from CMMRD patients 
displayed methylation tolerance. One, two or three rounds of MNNG treatment at 24-hour 
intervals were performed. LCLs from the 3 CMMRD patients (red) were phenotypically 
distinguishable from heterozygous (green) and wild-type (blue) LCLs using several 
experimental conditions. (D) 6-TG response of LCLs from the 3 CMMRD patients (red), 4 
LS patients (green) and one individual with wild-type MMR status (blue). 
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Figure 2. Flow diagram of patient study cohort. 
The functional assay, which includes the evMSI and methylation tolerance tests, allowed 
either the diagnosis or exclusion of CMMRD. 
DM, deleterious mutation; VUS, variant of unknown significance; LCL, lymphoblastoid cell 
line. 
 
Figure 3. Tolerance of immortalized lymphoblasts derived from 14 CMMRD patients and a 
series of MMR-proficient controls (including LS patients and MMR wild-type individuals) to 
increasing concentrations of MNNG.  
Because of the short half-life of MNNG in aqueous solution, 1, 2 or 3 pulses of treatment 
were performed. With the exception of MLH1+/- LCLs (n=11) that behaved similarly to MMR 
wild-type lymphoblasts (n=12) in all experimental conditions, MSH2+/- (n=12), PMS2+/- (n=4) 
and mainly MSH6+/- cell lines (n=13) exhibited increased cell survival under low MNNG 
concentrations. At higher MNNG concentrations and/or increasing numbers of drug 
treatments, the survival of MSH2+/-, PMS2+/- and MSH6+/- lines decreased towards that of 
MLH1+/- and MMR wild-type cells, whereas CMMRD LCLs remained quite tolerant to the 
drug. The best experimental condition to discriminate CMMRD patients from controls was 
two rounds of 2.5µM MNNG (red box). Patients with CMMRD or LS are represented with 
distinct colors depending on the MMR gene that was mutated (red for PMS2, blue for 
MSH6, yellow for MSH2 and green for MLH1).  
 
Figure 4. evMSI and methylation tolerance assays in a case-control study (A) and in 
patients considered at-risk for this syndrome (B). 
A. Case-control study involving 14 CMMRD patients and 23 MMR-proficient controls 
comprising 12 LS patients with heterozygous mutations affecting MMR genes and 11 
patients with no detected germline MMR mutation. EvMSI assay (left): Deletion sizes (in 
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base pair, bp) are expressed as the sum of the deletions for the 3 markers (NR27, NR21 
and BAT26). The cut-off value used to define a cell line as positive for evMSI was set at 1 
bp deletion for all 3 markers (red dotted line). LCLs from all 14 CMMRD patients showed 
decreased allele size, regardless of which MMR gene was mutated, whereas no deletions 
were detected in the 23 MMR-proficient controls tested. Methylation tolerance assay 
(right): Survival (%) of immortalized lymphoid cells derived from the same 14 CMMRD 
patients and from controls after 2 rounds of 2.5 µM MNNG treatment. Since some LS 
patients displayed increased tolerance to MNNG compared to MMR wild-type controls, a 
larger series of LS patients was used for the drug assay. Whereas MLH1+/- LCLs behaved 
similarly to MMR wild-type lymphoblasts, MSH2+/- and especially MSH6+/- cell lines 
exhibited significantly increased median cell survival. Overall, all CMMRD-derived LCLs 
displayed cell survival higher than 60%, whereas cell survival of all MMR-proficient LCLs 
was lower than 40%, with the exception of one case. The cut-off value was arbitrarily set at 
50% cell survival (red dotted line). Student’s t test. 
B. evMSI (left) and methylation tolerance (right) tests were applied for the detection of 
CMMRD syndrome in 23 patients with a clinical presentation suggestive of CMMRD, but for 
whom the diagnosis could not be confirmed (or excluded) by sequencing of MMR genes. 
These comprised of 8 patients with bi-allelic MMR alterations involving one or two VUS, 5 
patients with a single MMR alteration and 10 patients without germline MMR mutation. One 
of the latter (patient C29.1) showed abnormal functional assay results for both tests, which 
prompted us to perform additional PMS2 genetic screening that led to the identification of a 
homozygous deletion. 
Vertical line=VUS, cross=deleterious mutation.  
CMMRD and LS patients are represented using distinct colors depending on the MMR gene 
that was mutated.  
 
Figure 5. Proposed algorithm for the evaluation of patients suspected of having CMMRD. 
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In the next future, individuals with a clinical score of ≥3 according to Wimmer et al. 9 should 
be initially tested by functional assays. Since this approach has a high NPV, a normal result 
obtained with the functional assays would confidently allow the diagnosis of CMMRD to be 
excluded without the need for additional tests. Alternatively, an abnormal result would be 
highly suggestive of CMMRD. However, due to the relatively low PPV (80.5%) associated 
with this assay, we recommend that medical geneticists and pediatricians further 
investigate these ‘at-very-high-risk’ cases using other approaches (IHC, gMSI, sequencing 
of MMR genes) in order to confirm the diagnosis. It is worth noting that IHC results can be 
used to guide germline mutation analysis to a specific MMR gene, whereas in this context 
the finding of a normal gMSI ratio would direct genetic analysis to the MSH6 gene.  
* LS should be sought in cases with evocative criteria 
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Patient Clinical   Germline MMR analysis Publication or physician (country) scorea Gene Mutation type  Class b Status  
CMMRD patients with confirmed molecular diagnosis, i.e. with bi-allelic pathogenic MMR gene alterations 
C01.1 7 PMS2 Frameshift / Missense DM / DM Compound heterozygous  Auclair et al., 2007 32 
C01.2 7 PMS2 Frameshift / Missense DM / DM Compound heterozygous  Auclair et al., 2007 32 
C02 3 PMS2 Frameshift / Frameshift DM / DM Homozygous Ilencikova (Slovakia) 
C03.1 8 PMS2 Frameshift / Frameshift DM / DM Homozygous patient 1 in Chmara et al., 2013 33  
C03.2 9 PMS2 Frameshift / Frameshift DM / DM Homozygous patient 1.2 in Chmara et al., 2013 33 
C04 7 PMS2 Large deletion / Large deletion DM / DM Compound heterozygous  patient 2 in Chmara et al., 2013 33 
C05 10 PMS2 Nonsense / Nonsense / Frameshift DM / DM / DM Compound heterozygous  Brugières (France) 
C06  8 PMS2 Splice / Splice DM / DM Homozygous Brugières (France) 
C07 8 PMS2 Missense / Missense DM / DM Homozygous Colas (France) 
C08 8 PMS2 Missense / Missense DM / DM Homozygous Malka (France) 
C09.1 5 PMS2 Splice / Splice DM / DM Homozygous Brugières (France) 
C10 4 PMS2 Splice / Splice DM / DM Homozygous Brugières (France) 
C11 11 PMS2 Large deletion / Large deletion DM / DM Homozygous Fedhila / Colas (Tunisia) 
    MSH2 Missense VUS Heterozygous   
    MSH6 Missense VUS Heterozygous   
C12 5 MSH6 Frameshift / Frameshift DM / DM Homozygous patient PIV.5 in Ilencikova et al., 2011 34 
C13.1 10 MSH6 Frameshift / Frameshift DM / DM Compound heterozygous  patient P6 in Gardes et al., 2012 35 
C14 8 MSH6 Frameshift / Frameshift DM / DM Compound heterozygous  Auclair et al., 2007 32 
C15  10 MLH1 Splice / Splice DM / DM Homozygous Entz Werle (France) 
C16 9 MLH1 Missense / Missense DM / DM Homozygous Raevaara et al., 2004 36 
C17 6 MSH2 Large deletion / Large deletion DM / DM Homozygous Verloes (France) 
Patients with clinical characteristics of CMMRD syndrome but a lack of confirmatory standard genetic defect  
C18  6 PMS2 In frame deletion / Missense DM / VUS Compound heterozygous  Lejeune (France) 
C19 8 PMS2 Missense / Frameshift VUS / DM Compound heterozygous  Dramard (France) 
C20.1 7 MSH6 Missense / Missense VUS / VUS Homozygous Leis (Afghanistan) 
C20.2 7 MSH6 Missense / Missense VUS / VUS Homozygous Leis (Afghanistan) 
C21 14 MSH6 Frameshift / In frame deletion DM / VUS Compound heterozygous  Bougeard et al. 2014 29 
    MSH2 Missense VUS Heterozygous   
C22 8 MSH6 Missense / Missense VUS / VUS Homozygous Wafaa / Colas (Marocco) 
    PMS2 Missense VUS Heterozygous   
C23 13 MSH6 
In frame duplication / In frame 
duplication  VUS / VUS Heterozygous Gauthier-Villars (France) 
 
C24 6 MSH2 Splice / Splice DM / VUS Compound heterozygous  Ruiz Ponte (Spain) 
C25 5 PMS2 Frameshift DM Heterozygous Colas (France) 
C26 4 PMS2 Large deletion DM Heterozygous Kinzel (Germany) 
C27 3 MLH1  Frameshift DM Heterozygous Colas (France) 
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 2  
    MSH2 Missense VUS Heterozygous   
C28 1 MLH1 Splice DM Heterozygous Caron (France) 
C29.1 4 - no MMR mutation identified c  -  - Brugières (France) 
C30 4 MSH2 Splice VUS Heterozygous Brugières (France) 
C31 3 - no MMR mutation identified   -  - Mortemousque (France) 
C32 3 - no MMR mutation identified   -  - Brugières (France) 
C33 4 - no MMR mutation identified   -  - Wang (France) 
C34.1 4 - no MMR mutation identified   -  - Grandjouan (France) 
C35 6 - no MMR mutation identified   -  - Brugières (France) 
C36 3 - no MMR mutation identified   -  - Grandjouan (France) 
C37 4 - no MMR mutation identified   -  - Colas (France) 
C29.2 NA - no MMR mutation identified c  -  - Brugières (France) 
C34.2 4 - no MMR mutation identified   -  - Brugières (France) 
       
 
Table 1. Data set for known and putative CMMRD patients 
 
a
  Clinical score according to Wimmer et al. 
9
; NA, not applicable 
b
  DM, deleterious mutation; VUS, variant of unknown significance 
c
  Extensive genetic screening was performed post-hoc in view of the abnormal functional assay results found in patient 
C29.1. It led to the identification of a homozygous deletion of exons 14-15 of the PMS2 gene, c.276-? (*160?) del, while 
the brother (patient C29.2) was found as heterozygote for the PMS2 deletion. 
Detailed description of the MMR gene alterations is provided in supplementary table 1
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 3  
A. 
Patient 
MMR sequencing Functional assays Diagnosis 
according to 
functional 
assays  
Comparison with other tests 
status MMR gene evMSI methylation gMSI MMR protein expression 
        tolerance   in normal tissue (IHC) 
CMMRD patients n=14         
  
    
C15 hmz DM MLH1 
    
CMMRD 
  
lost 
C06, C07, C08, C09.1 hmz DM PMS2 
      
lost 
C10 hmz DM PMS2 + + + NA 
C04, C05  cpd htz DM PMS2 
      
lost 
C01.1  cpd htz DM PMS2 
      
NA 
C01.2 cpd htz DM PMS2 + + NA lost 
C02 hmz DM PMS2 
+ + NI 
NA 
C14 cpd htz DM MSH6 lost 
C12 hmz DM MSH6 
+ + - 
NA 
C13.1 cpd htz DM MSH6 NA 
Patients at-risk for CMMRD n=23         
  
  
  
C29.1 no mutationa + + 
CMMRD 
+ lost 
C20.1  hmz VUS MSH6 
+ + - 
lost 
C20.2, C22  hmz VUS MSH6 conserved 
C18 DM + VUS PMS2 lost 
C19 DM + VUS PMS2 + + NI lost 
C24 DM + VUS MSH2 
- - not CMMRD - 
conserved 
C30 htz VUS MSH2 NA 
C25 htz  DM PMS2 lost 
C26 htz  DM PMS2 conserved 
C27 htz  DM MLH1          NA           
C28 htz  DM MLH1 conserved 
C34.2 no mutation conserved 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 
 4  
 
C29.2, C31, C32, C34.1, C35, C36, C37 no mutationa NA 
C33 no mutation - - NI NA 
C21 DM + VUS MSH6 
- + Doubtful - 
lost 
C23 hmz VUS MSH6 lost 
        
 Table 2. evMSI, methylation tolerance, gMSI and IHC data in the series of 14 CMMRD patients with bi-allelic pathogenic MMR gene alterations and in 23 
patients at-risk for whom diagnosis could not be confirmed by MMR sequencing.   
 
       
a
 extensive genetic screening that was performed post-hoc led to the identification of a deletion of exons 14-15 in the PMS2 gene that was found at an 
homozygous or heterozygous status in patients C29.1 and C29.2, respectively. 
 
       
Detailed data on the expression of MMR proteins in normal tissue and on gMSI test are provided in supplementary tables 1 to 
3.  
VUS, variant of unknown significance; DM, deleterious mutation; hmz, homozygous; htz, heterozygous; cpd, compound;  +, positive/abnormal; 
 -, negative/normal; NI, not interpretable; NA, not available.  
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A.
status MMR gene ev MSI methylation gMSI MMR protein expression
tolerance in normal tissue (IHC)
CMMRD patients n=14
C15 hmz DM MLH1 lost
C06, C07, C08, C09.1 hmz DM PMS2 lost
C10 hmz DM PMS2 + + + NA
C04, C05 cpd htz DM PMS2 lost
C01.1 cpd htz DM PMS2 NA
C01.2 cpd htz DM PMS2 + + NA lost
C02 hmz DM PMS2 NA
C14 cpd htz DM MSH6 lost
C12 hmz DM MSH6 NA
C13.1 cpd htz DM MSH6 NA
Patients at-risk for CMMRD n=23
C29.1 + + + lost
C20.1  hmz VUS MSH6 lost
C20.2, C22  hmz VUS MSH6 conserved
C18 DM + VUS PMS2 lost
C19 DM + VUS PMS2 + + NI lost
C24 DM + VUS MSH2 conserved
C30 htz VUS MSH2 NA
C25 htz  DM PMS2 lost
C26 htz  DM PMS2 conserved
C27 htz  DM MLH1          NA          
C28 htz  DM MLH1 conserved
C34.2 conserved
C29.2, C31, C32, C34.1, C35, C36, C37 NA
C33 - - NI NA
C21 DM + VUS MSH6 lost
C23 hmz VUS MSH6 lost
Detailed data on the expression of MMR proteins in normal tissue and on gMSI test are provided in supplementary tables 1 to 3.
 -, negative/normal; NI, not interpretable; NA, not available. 
 Table 2. ev MSI, methylation tolerance, gMSI and IHC data in the series of 14 CMMRD patients with bi-allelic pathogenic MMR gene alterations and in 
patients at-risk for whom diagnosis could not be confirmed by MMR sequencing.  
a
 extensive genetic screening that was performed post-hoc  led to the identification of a deletion of exons 14-15 in the PMS2  gene that was found at an
homozygous or heterozygous status in patients C29.1 and C29.2, respectively.
VUS, variant of unknown significance; DM, deleterious mutation; hmz, homozygous; htz, heterozygous; cpd, compound;  +, positive/abnormal;
Comparison with other tests
no mutationa
NI
-
-CMMRD
Diagnosis 
according to 
functional 
assays 
+
+ +
CMMRD
Patient
MMR sequencing
+
no mutation
Functional assays
-
no mutationa
-
+ +
no mutation
-
-- + Doubtful
not CMMRD
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SUPPLEMENTARY MATERIAL AND METHODS 
 
Patients. All of the 19 genetically confirmed and 19 of the 23 suspected CMMRD 
patients included in this study had a score ≥3 points according to the recently 
published clinical criteria for the suspected diagnosis of CMMRD. Additionally, four 
patients were included in this study. One patient (C28) was included because he 
displayed a very severe clinical history with four LS-related tumors from 32 to 36 year 
and osteosarcoma at the age of 11 years old (osteosarcoma was found in the 
CMMRD patient C05 at the age of 24 years old). Equally, one patient (C27) was 
included since, compared to other members of this LS family, he had a very early 
onset (30 years) of two synchronous colon cancers with an adenoma and a brother 
who had a malignant brain tumour at the age of 18 years. Another patient (C33) had 
a cerebral tumor at the age of 27 years old as well as CALMs and her sister 
displayed a cerebral tumor (22 years). Finally, one was an asymptomatic sibling with 
CALMs of a possible CMMRD patient (C29.2). Altogether, the study included 42 
patients (37 families) from several European cancer centers. Control subjects 
considered free of MMR germline defects included five FAP and two NF1 individuals 
with identified germline APC or NF1 mutations, respectively (FAP and NF1 were 
chosen because they represent cancer predisposition syndromes showing clinical 
overlap with CMMRD) and eight control patients diagnosed with sporadic colorectal 
cancer without familial cancer history. These patients had developed microsatellite 
stable tumors (6 cases) or MSI tumors due to epigenetic silencing of MLH1 because 
of somatic methylation (2 cases) and thus were not suspected of having CMMRD 
syndrome.  
Colorectal cell lines. Human colorectal cancer cell lines were grown in DMEM with 
glutamax supplemented with 10% FCS, 100 IU/ml penicillin and 100mg/ml 
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streptomycin (PAA). They included 6 microsatellite unstable (HCT116, LIM2405, 
LS174T, KM12 (all MLH1-deficient), HCT15 (MSH6 mutated) and LoVo 
(homozygous deletion of exons 2-8 of MSH2)) and 5 microsatellite stable (LS513, 
SW620, Caco-2, FET and HCT116 mlh1-2 (HCT116 transfected with an MLH1-
expression vector 1) cell lines.  
Treatment of colorectal cell lines. Cells in the exponential growth phase were 
counted by trypan blue exclusion and seeded into 24-well plates (Falcon) at a density 
of 0.2-5×105 cells/well in complete medium. After 24-h incubation, 6-TG (1, 5, 15, 
20µM final concentrations) or extemporaneously reconstituted MNNG (0.1, 1, 5, 
20µM final concentrations) was added. Medium was removed and replaced with 
fresh medium after 24-h or 1-h incubation, respectively. Cell growth was evaluated 
after a total incubation period of 7 to 9 days. To exclude differences in MNNG 
cytotoxicity due to variations in O6-methylguanine methyltransferase enzyme activity, 
the latter was abrogated by exposure to O6-benzylguanine (20µM final concentration) 
during the entire experiment. All samples were tested in quadruplicate. 
6-TG treatment of lymphoblastoid cell lines. Cells suspended in complete medium 
(3x105 cell/mL) were distributed into 6 microtubes with increasing concentrations of 6-
TG (0.15, 0.3, 0.6, 1.25 and 2.5µM final concentrations) into 5 of them. After 24-h 
incubation, all microtubes were centrifuged, the cells were rinsed with fresh medium 
and then seeded in 100µL aliquots into 96-well round-bottom plates (0.6×104 
cells/well). Cell growth was evaluated after a total incubation time of 7 days and all 
samples were tested in sextuplicate. 
DNA extraction for evMSI and gMSI assays. Ficoll-Plaque PLUS was used to 
isolate human lymphocytes from blood patients, according to the supplier’s 
recommendations (GE Healthcare). DNA extraction from lymphocytes or LCL was 
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performed using QIAmp DNA kit according to the supplier’s recommendations 
(Qiagen).  
Determining the gMSI ratio. Multiplex PCR amplification in triplicate (denaturation 
of 95°C for 2 min, followed by 35 cycles of 95°C fo r 30sec, 55°C for 30sec, and 72°C 
for 60sec, with a final extension at 72°C for 10min ) of the dinucleotide microsatellite 
markers D17S791, D2S123 and D17S250 was developed using the primers 
previously described 2, and using 10ng of patient germinal DNA. PCR products were 
separated by capillary electrophoresis on an ABI3100 genetic analyzer and 
quantified using Gene Mapper software v3.7.  Briefly, the gMSI ratio was determined 
by dividing the height of an allele’s trailing “stutter” peak (n+1) by the height of the 
allele’s major peak (n). Interpretation required that the size difference between alleles 
in heterozygous individuals was ≥6bp 2. 
Statistical analysis. We developed a Bayesian approach to conduct inference for 
the unknown prevalence, sensitivity and specificity of the three diagnostic methods 
as performed in Joseph et al. 3. Our setting was however different from theirs, in 
particular we knew the true disease status for controls and genetically confirmed 
CMMRD patients, which removes the lack of identifiability of Joseph et al. approach 
pointed out in Johnson et al. 4. 
In the saturated model, the joint distribution of the tests or combination of tests was 
assumed to be multinomial with 16 categories, corresponding to all possible 
observations. The multinomial parameters were expressed as the true proportion of 
confirmed CMMRD patients, sensitivity and specificity of the tests. We assumed 
conditional independence of the tests to ensure identifiability in the unsaturated 
model. A Metropolis-Hastings algorithm was run on the data to estimate the seven 
parameters and two-sided confidence intervals3, 5. Let D be the true CMMRD status 
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(+/-), T1 (+/-), T2 (+/-) and T3 (+/-) be the result of MMR gene sequencing, functional 
testing and gMSI testing, respectively. The true proportion of CMMRD patients, 
sensitivity and specificity of the three tests or combination of tests are defined as: 
 
 
The observed data are summarized in the table below (the rows with no observations 
are not reported), the usual latent variables are denoted by X, Y, Z. 
 
 
 
We particularized MSH6 cases, since gMSI is not relevant to identify CMMRD 
patients with MSH6 defects. As a consequence, we rewrite  
 
conditionally to the parameters. 
Genetic 
testing 
 
 
Methylation 
tolerance and 
evMSI 
gMSI 
 
 
True 
status 
 
 
Data 
+ + + CMMRD+ 9 
+ + - CMMRD+ 2 
- - - CMMRD+ Y 
- - - CMMRD- 9+15-Y 
- + + CMMRD+ X 
- + + CMMRD- 1-X 
- + - CMMRD+ Z 
- + - CMMRD- 4-Z 
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This formulation allowed us to fit the model through the Metropolis-Hastings 
algorithm 6. In the latter, we considered a Dirichlet prior for the joint distribution of the 
seven parameters. The parameters of the marginal prior distributions were chosen as 
(1,1) for the true proportion of CMMRD patients, the sensitivities and the specificities. 
The Metropolis-Hastings algorithm was run on 50000 iterations and the last 25000 
iterations were used to derive estimations and confidence intervals for the 
sensitivities, specificities, positive and negative predictive values of MMR gene 
sequencing, functional testing and gMSI testing. The same procedure has been 
applied for the comparison between MMR gene sequencing and functional testing. 
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Legends 
 
Supplementary figure 1. Tolerance of human colon cancer cell lines to increasing 
concentrations of MNNG (A) and 6-TG (B).  
Regardless of the defective MMR gene, MMR-deficient colon cancer cell lines (red 
symbols) showed statistically significant increases (10-fold using 1µM MNNG and 2-
fold using 15µM 6-TG) in mean cell survival compared with MMR-proficient cell lines 
(blue symbols). Mean ± SD. * for P<0.05, ** for P<0.01, *** for P<0.001; ns, not 
significant ; Student’s t test. 
 
Supplementary figure 2. Pedigrees of all previously unreported patients with 
indications for LS- or CMMRD-related (filled symbols) and other (striped symbols) 
malignancies / pre-malignancies and age at diagnosis (in years). 
Arrows indicated the patients included in the study and their concise MMR genotype 
is shown (bold characters). Ad, adenoma ; AML, acute myeloid leukemia; C, cancer ; 
CALMs, café-au-lait macules; CRC, colorectal cancer; CT, cerebral tumor; DM, 
deleterious mutation; EC, endometrial cancer; hmz, homozygous; htz, heterozygous; 
mut, mutation; VUS, variant of unknown significance. 
 
Supplementary figure 3. Tolerance of immortalized lymphoblasts derived from 14 
CMMRD patients and a series of MMR-proficient controls (including LS patients and 
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MMR wild-type individuals) to increasing concentrations of 6-TG.  
Patients with CMMRD or LS are represented with distinct colors depending on which 
MMR gene was mutated (red for PMS2, blue for MSH6, yellow for MSH2 and green 
for MLH1).  
 
Supplementary figure 4. Histogram showing gMSI ratios at each marker (D17S791, 
D2S123 and D17S250) for the 18 CMMRD patients tested (the deficient MMR gene 
is indicated) and for a series of 19 LS patients and 220 controls from the Human 
Genome Diversity Panel.  
Error bars represent the standard error of the mean. The horizontal blue, red and 
green lines indicate the gMSI cut-off values for markers D17S791, D2S123 and 
D17S250, respectively. Test result is positive (i.e. abnormal) when the gMSI ratios of 
at least 2 markers are above the cut-off value, and negative (i.e. normal)  when the 
gMSI ratios of at least 2 markers are below the cut-off value. Otherwise, the result is 
considered as not interpretable which made the test non-informative in 3/18 (16.7%) 
CMMRD patients (labeled with *), 3/19 (15.8%) LS patients and 39/220 (17.7%) 
controls. The two CMMRD patients with MSH6 deficiency (C12 and C13.1) were not 
detected by this method whereas CMMRD patients with PMS2, MLH1 or MSH2 
deficiency displayed abnormal gMSI values. All controls were negative. 
 
 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
Clinical Familial 
scoreb historyc Gene Exon  Mutation (Amino-acid change) Type Class e
C01.1 oligodendroglioma (19); two colorectal cancers (MSI) (24)                                              7 S, R PMS2 11 c.1730dup ; p.Arg578Alafs*3 Frameshift DM
4 c.137G>T ; p.Ser46Ile Missense DM
C01.2 7 S, R PMS2 11 c.1730dup ; p.Arg578Alafs*3 Frameshift DM
4 c.137G>T ; p.Ser46Ile Missense DM
C02 glioblastoma (4) 3 Co, R PMS2 15 c.2521del ; p.Trp841Glyfs*10 Frameshift DM
15 c.2521del ; p.Trp841Glyfs*10 Frameshift DM
C03.1 pilomatricomas (PMS2 lost in N and T) (2), oligodendroglioma (11) 8 S, Co PMS2 11 c.1164del ; p.His388Glnfs*10 Frameshift DM
11 c.1164del ; p.His388Glnfs*10 Frameshift DM
C03.2 9 S, Co PMS2 11 c.1164del ; p.His388Glnfs*10 Frameshift DM
11 c.1164del ; p.His388Glnfs*10 Frameshift DM
C04 7  - PMS2 7-9 c.706-?_903+?del ; p.? Large deletion DM
9-15 c.904-?_*+?del ; p.? Large deletion DM
C05 10 Co PMS2 5 c.400C>T ; p.Arg134* Nonsense DM
5 c.400C>T ; p.Arg134* Nonsense DM
11 c.1579del ; p.Arg527Glyfs*68 Frameshift DM
C06 8 Co PMS2 12 c.2007-2A>G ; p.? Splice DM
12 c.2007-2A>G ; p.? Splice DM
C07 8 P, Co PMS2 2 c.137G>T ; p.Ser46Ile Missense DM
2 c.137G>T ; p.Ser46Ile Missense DM
C08 8  - PMS2 2 c.137G>T ; p.Ser46Ile Missense DM
2 c.137G>T ; p.Ser46Ile Missense DM
C09.1 CALMs; lymphoblastic lymphoma (4); PMS2 lost in normal skin 5  Co PMS2 12 c.2007-2A>G ; p.? Splice DM
12 c.2007-2A>G ; p.? Splice DM
C10 CALMs; glioblastoma (6) 4 Co PMS2 12 c.2007-2A>G ; p.? Splice DM
12 c.2007-2A>G ; p.? Splice DM
C11 11 S PMS2 14 c.2275+210_2446-1356del ; p.Ala759Glyfs*8 Large deletion DM
14 c.2275+210_2446-1356del ; p.Ala759Glyfs*8 Large deletion DM
MSH2 4 c.728G>A ; p.Arg243Gln Missense VUS
MSH6 i3 c.627+25_627+27del ; p.? Missense VUS
CALMs; colorectal cancer (MSI / PMS2 normal at 1rst analysis; lost in N and T at 2nd look) 
with 12 adenomas (20); endometrial cancer (24)
T-cell lymphoblatic mediastinal lymphoma (14), colorectal cancer with polyposis (16)
CALMs; colorectal cancer (19); colorectal cancer (MSI / PMS2 lost in N and weak in T) (20); 
lymphoblastic lymphoma (27)
CALMs; pilomatricomas (2), pre B-cell non Hodgkin lymphoma (3); glioblastoma (9)
glioblastoma (22);  colorectal cancer (MSI / PMS2 lost in N and T) with three adenomas (24); 
osteosarcoma (24); acute myeloblastics leukemia (30)
Patient Clinical and tumor dataa
CMMRD patients with confirmed molecular diagnosis, i.e. with bi-allelic pathogenic MMR gene alterations
 Germline MMR analysis
CALMs; testicular T-lymphoblastic lymphoma (5 and 14); rectal cancer (MSI/PMS2 lost in N 
and T) (16)
no CALMs; colorectal cancer (22); colorectal cancer (MSI/PMS2 lost in N and T) (25); 
glioblastoma (34); endometrial cancer (PMS2 lost in N and T) (36); duodenal cancer 
(MSS/PMS2 lost in N and T) (37); benin sebaceous cyst (37); multiple colorectal adenomas 
(>15) (since 22)
CALMs; glioblastoma (4);  B-cell non Hodgkin lymphoma (5); pilomatricomas (PMS2 lost in N 
and T)
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C12 5 Co, R MSH6 5 c.3261dupC ; p.Phe1088Leufs*5 Frameshift DM
5 c.3261dupC ; p.Phe1088Leufs*5 Frameshift DM
C13.1 10 S, R MSH6 9 c.3984_3987dup ; p.Leu1330Valfs*12 Frameshift DM
9 c.3959_3962del ; p.Ala1320Glufs*6 Frameshift DM
C14 8 S, R MSH6 4 c.1596_1597dup ; p.Glu533Valfs*39 Frameshift DM
5 c.3261del ; p.Phe1088Serfs*2 Frameshift DM
C15 10 Co, S, R MLH1 9 c.678-7_686del ; p.? Splice DM
9 c.678-7_686del ; p.? Splice DM
C16 9 Co MLH1 17 c.1942C>T ; p.Pro648Ser Missense DM
17 c.1942C>T ; p.Pro648Ser Missense DM
C17 CALMs; cavernoma (3), T-cell lymphoblastic lymphoma (3) 6 P, Co MSH2 8 c.1277-?_c.1386+? ; p.? Large deletion DM
8 c.1277-?_c.1386+? ; p.? Large deletion DM
C18 6 R PMS2 10 c.989?_1144+?del ; p.Glu330_Glu381del In frame deletion DM
13 c.2249G>A ; p.Gly750Asp Missense VUS
C19 Colorectal cancer  (MSI / PMS2 lost in N and T) (21); glioblastoma (22) 8 S, R PMS2 2 c.161T>C ; p.Ile54Thr Missense VUS
11 c.1831dup ; p.Ile611Asnfs2* Frameshift DM
C20.1 CALMs; gliomatosis (MSS /MSH6 lost in N and T) (9) 7 Co, S MSH6 4 c.2216C>A ; p.Thr739Lys Missense VUS
4 c.2216C>A ; p.Thr739Lys Missense VUS
C20.2 CALMs; glioblastoma (MSS / MSH6 weak in N and T) (6) 7 Co, S MSH6 4 c.2216C>A ; p.Thr739Lys Missense VUS
4 c.2216C>A ; p.Thr739Lys Missense VUS
C21 14 S, R MSH6 5 c.3261dupC ; p.Phe1088Leufs*5 Frameshift DM
4 c.2561_2563del ; p.Lys854del In frame deletion VUS
MSH2 5 c.832G>A ; p.Glu278Lys Missense VUS
C22 CALMs; colorectal cancer  (MLH1, MSH2, PMS2, MSH6 normal in N) (16) 8 Co, S MSH6 5 c.3184T>C ; p.Cys1062Arg Missense VUS
5 c.3184T>C ; p.Cys1062Arg Missense VUS
PMS2 11 c.1688G>T ; p.Arg563Leu Missense VUS
C23 13 Co MSH6 4 c.1763_1771dup ; p.His588_Pro590dup In frame duplication VUS
4 c.1763_1771dup ; p.His588_Pro590dup In frame duplication VUS
C24 6 R MSH2 i6 c.1076+1G>A ; p.Gly315Ilefs*29 Splice DM
i6 c.1077-11A>G ; p.? Splice VUS
C25 5  R PMS2 11-14 large genomic conversion with PMS2CL ; p.? Frameshift DM
CALMs; multiple adenomas (MSS / MSH6 lost in N and T) with high grade dysplasia (9) 
CALMs; T-non Hodgkin lymphoma (2) since publication
CALMs; colon adenomas (10), glioblastoma (12.5); MSH6 lost in tumor of the sister
Patients with clinical characteristics of CMMRD syndrome but a lack of confirmatory standard genetic defect 
CALMs; adenomas (14); colorectal cancer (17 and 19); urinary tract carcinoma (MSS / MSH6 
lost in N and T) (24) 
CALMs; lymphoblastic lymphoma (MSS/ MLH1 lost in N and T) (5); glioblastoma (MLH1 lost 
in N and T) (6)
CALMs; colorectal cancer (22); colorectal cancer (MSI/PMS2 lost in N and T) with adenoma 
(32); multiple adenomas with high grade dysplasia (38); glioblastoma (40)
CALMs; neurofibroma (6); several adenomas and rectal cancer (15) since publication
CALMs; T-cell lymphoblastic lymphoma (6 and 11); glioblastoma (14); colorectal cancer 
(MSS/MLH1, MSH6, MSH2 normal at 1rst analysis; MSH2 and MSH6 lost in N and T at 2nd 
look) with polyposis (14)
no CALMs; colorectal cancer (MSH2 normal in N, lost in T) (12); 1 skin nodule (neurofibroma 
histologically not confirmed)
CALMs; colorectal cancer (MSI, MLH1 lost in T;  PMS2 lost in N and T) (25); breast cancer 
(36)
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C26 4 S, R PMS2 i11-i12 Large deletion DM
C27 two colorectal cancers with one adenoma >1cm (30) 3 S, P, R MLH1 9 c.769del ; p.Ile257Serfs*11 Frameshift DM
MSH2 5 c.832G>A ; p.Glu278Lys Missense VUS
C28 1  - MLH1 15 c.1731G>A ; p.Ser577Ser Splice DM
C29.1 CALMs; glioblastoma (PMS2 lost in N and T) (6) 4 R  -  - no MMR mutation identified d  -  -
C30 CALMs; T-cell lymphoblastic lymphoma (8) 4  - MSH2 i4 c.792+16A>G ; p.? Splice VUS
C31 3  -  -  - no MMR mutation identified  -  -
 
C32 Hodgkin lymphoma (11) 3 R  -  - no MMR mutation identified  -  -
C33 CALMs; oligodendroglioma (27) 4 S  -  - no MMR mutation identified  -  -
C34.1 colorectal tumor (MSI / MLH1 lost in T) (18) 4 S  -  - no MMR mutation identified  -  -
C35 CALMs; glioblastoma (18) 6 R, Co  -  - no MMR mutation identified  -  -
C36 colorectal tumor (MSI / MLH1 lost in T) (17) 3  -  -  - no MMR mutation identified  -  -
C37 4  R  -  - no MMR mutation identified  -  -
 
C29.2 CALMs NA S, R  -  - no MMR mutation identified d  -  -
C34.2 pinealoblastoma (MLH1, MSH6, MSH2, PMS2 normal in N and T) (12) 4 S  -  - no MMR mutation identified  -  -
CALMs; adenomatous polyposis (n>50) with duodenal adenomas (APC, MUTYH negative) 
(24); bilateral breast cancer (BRCA negative) (35 and 37); diffuse gastric cancer (CDH1 
negative) (39); duodenal adenoma with high grade dysplasia (40)    
lymphosarcoma (5); oligodendroglioma (MSS / MLH1, MSH2 normal in T) (21); thyroid cancer 
(29)
c.2007-786_2174+493del1447 ; 
p.Ser669_Ala725delinsArg
osteosarcoma (11); urothelial carcinoma (32 and 33); cholangiosarcoma (MLH1normal in N, lost 
in T) (36); colorectal cancer (MLH1 lost in T) (36); bladder carcinoma (37)
no CALMs; rectal cancer (17); colon cancer (MSI in N and T / PMS2 normal in N, lost in T) 
(27)
Supplementary Table 1. Data set relative to proved and putative CMMRD patients 
 
a  When available, data relative to the microsatellite status of the tumor, i. e. stable (MSS) or unstable (MSI), and to immunohistochemistry for MMR proteins in normal (N) and tumoral (T) tissues are 
indicated. Age at diagnosis is indicated in brackets. CALMs, café-au-lait macules 
b  Clinical score according to 9; NA, not applicable 
c  Co, consanguinity; S, sibling affected with CMMRD-associated cancer; P, parent affected with Lynch syndrome-associated cancer; R, relative affected with Lynch syndrome- or CMMRD-associated 
cancer 
d  Extensive genetic screening that was performed post-hoc in view of the abnormal functional assay results found in patient C29.1, led to the identification of a homozygous deletion of exons 14-15 of the 
PMS2 gene, c.276-? (*160?) del, while the brother (patient C29.2) was found as heterozygote for the PMS2 deletion 
e  DM, deleterious mutation; VUS, variant of unknown significance  
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Mutated Culture
gene 1.25µM 2.5µM 5µM 1.25µM 2.5µM 5µM 1.25µM 2.5µM 5µM BAT26 NR21 NR27  time
C01.1 PMS2 96.8 ± 14.1 93.9 ± 10.1 75.1 ± 17.7 108 ± 8.5 99.9 ± 6 22.3 ± 10.7 95.8 ± 12.1 90.1 ± 19.2 18.1 ± 4.8 178 / 178 / 0 106 / 106 / 0 86 / 84 / -2 X
C01.2 PMS2 85.6 ± 13.8 77.4 ± 16.4 29.7 ± 11.2 85.3 ± 9.6 69.6 ± 15.8 26.6 ± 11.1 72.8 ± 15.4 24.8 ± 10.8 13.2 ± 4.7 178 / 178 / 0 105 / 105 / 0 86 / 84 / -2 X
C02 PMS2 91.6 ± 18.6 97.5 ± 12.6 83.9 ± 12.2 96 ± 11.8 89.1 ± 9 90.9 ± 17.9 91.2 ± 15.8 91 ± 16.1 35.7 ± 8.1 179 / 178 / -1 105 / 105 / 0 87 / 86 / -1 78
C04 PMS2 92.5 ± 15 93 ± 17.8 46 ± 13.3 97.9 ± 12.4 89.4 ± 12 50.1 ± 18.6 99.1 ± 12.6 91.2 ± 14.5 72.1 ± 15.1 179 / 179 / 0 105 / 104 / -1 86 / 85 / -1 X
C05 PMS2 94.4 ± 13.6 79.6 ± 15.2 31.4 ± 10.7 94.9 ± 10.6 79.6 ± 15.6 40.5 ± 17.3 98.1 ± 7.3 77.7 ± 15.1 27.5 ± 12.5 180 / 179 / -1 105 / 103 / -2 85 / 84 / -1 46
C06 PMS2 85.3 ± 16.6 61.6 ± 10 53.1 ± 14.1 98 ± 11.6 64.2 ± 17.6 23.8 ± 5.5 98.6 ± 12.7 53.1 ± 11 18.2 ± 1.5 180 / 178 / -2 106 / 105 / -1 86 / 86 / 0 81
C07 PMS2 84.6 ± 7.4 72.9 ± 12.6 57.3 ± 10.4 95.3 ± 17.8 83.2 ± 17.7 87 ± 16.3 82.2 ± 15.7 63.5 ± 13.5 72.1 ± 14.3 182 / 182 / 0 105 / 105 / 0 86 / 85 / -1 100
C08 PMS2 93.3 ± 8 90.3 ± 13.1 79.3 ± 15.7 99.3 ± 8.4 89.5 ± 10.9 53.2 ± 15.4 91.7 ± 11.8 73.5 ± 12 29.4 ± 6.7 178 / 177 / -1 105 / 104 / -1 86 / 85 / -1 82
C09.1 PMS2 112.4 ± 15 106.4 ± 10.9 111 ± 11.6 113.4 ± 14.8 99.6 ± 14.2 102.9 ± 12.9 93.9 ± 16.8 96.8 ± 14.5 84.1 ± 8.7 181 / 180 / -1 105 / 105 / 0 86 / 86 / 0 120
C10 PMS2 103.2 ± 12.4 81.4 ± 14.3 86.2 ± 17.6 91.9 ± 14.4 81.6 ± 11.3 40.2 ± 16 91.9 ± 8.2 65.5 ± 18.8 34.8 ± 16.8 180 / 180 / 0 105 / 105 / 0 86 / 85 / -1 115
C12 MSH6 103.3 ± 13.3 98 ± 18.5 97.7 ± 14.9 102.5 ± 11 93.8 ± 20.1 105.6 ± 8.7 90.2 ± 15.7 96.1 ± 13.7 89 ± 8.1 181 / 181 / 0 105 / 105 / 0 87 / 86 / -1 80
C13.1 MSH6 99.5 ± 9.3 85.2 ± 15.3 81.1 ± 13 100.1 ± 17.7 83.9 ± 17.9 43 ± 9.9 97.8 ± 14.5 63.4 ± 18.1 25.7 ± 6.3 179 / 178 / -1 106 / 106 / 0 86 / 86 / 0 70
C14 MSH6 92.5 ± 14.1 96.1 ± 11.6 96.7 ± 11.2 106.4 ± 8.8 101.8 ± 8.6 104.6 ± 13.4 90.1 ± 8.6 91.8 ± 15.9 97 ± 8.9 178 / 175 / -3 105 / 104 / -1 87 / 84 / -3 X
C15 MLH1 101.1 ± 8.5 99.4 ± 16.3 84.3 ± 11.5 108.2 ± 14.2 99.5 ± 14.7 81.9 ± 16.1 84.2 ± 11.8 77.6 ± 16.3 53.6 ± 17.2 179 / 177 / -2 105 / 105 / 0 87 / 86 / -1 64
Patients at-risk for CMMRD 
C20.1 MSH6 85.6 ± 19.2 92 ± 18.8 67.8 ± 16.6 96.4 ± 14.5 96.2 ± 13.3 42.3 ± 6.7 85.6 ± 12.5 56.3 ± 9.7 27.9 ± 7.1 180 / 179 / -1 105 / 105 / 0 87 / 87 / 0 45
C20.2 MSH6 89.2 ± 15.3 80.3 ± 11.3 33.9 ± 7.7 77 ± 13.6 70.8 ± 16.5 17.1 ± 2.1 72.4 ± 13.6 47.4 ± 8.8 18.6 ± 5.1 180 / 179 / -1 105 / 105 / 0 87 / 86 / -1 45
C18 PMS2 92 ± 7.7 89.2 ± 3.1 79.9 ± 15.9 94.8 ± 8.4 89.2 ± 9.7 85 ± 16.4 90.8 ± 6 80.9 ± 6.8 59.3 ± 6.8 180 / 180 / 0 106 / 105 / -1 87 / 87 / 0 X
C27 MLH1 23.9 ± 11.3 14.2 ± 2 11.4 ± 1.6 18 ± 1.7 13.1 ± 1.2 11.3 ± 1 14.1 ± 2.5 11.4 ± 1.7 10.6 ± 1 180 / 180 / 0 105 / 105 / 0 86 / 86 / 0 182
C25 PMS2 16.7 ± 1.8 14.5 ± 2 14.8 ± 2.9 17.1 ± 2.1 15.3 ± 2.6 15.5 ± 2.3 18.9 ± 5.9 16.8 ± 2.7 16.3 ± 2.6 180 / 180 / 0 105 / 105 / 0 87 / 87 / 0 344
C22 MSH6 101.7 ± 5.3 93.8 ± 8 84.5 ± 7.6  108.2 ± 9.2 102.3 ± 12.2  83.1 ± 11.6 89.7 ± 16.2 78.2 ± 11.7 67.1 ± 12.5 180 / 179 / -1 105 / 105 / 0 87 / 87 / 0 68
C24 MSH2 90.1 ± 13.2 50.2 ± 17.1 22.1 ± 3.9 67.9 ± 12 24.3 ± 6.6 14.3 ± 1.3 50.7 ± 19.9 22 ± 5.6 13.4 ± 2 181 / 181 / 0 106 / 106 / 0 87 / 87 / 0 140
C30 MSH2 23.4 ± 7.2 17.1 ± 2.7 15.7 ± 2.4 20.9 ± 4.6 17.4 ± 2.5 15.1 ± 2.9 16.5 ± 5.4 16.1 ± 2.8 13.7 ± 3 180 / 180 / 0 106 / 106 / 0 87 / 87 / 0 125
C19 PMS2 97.4 ± 11.1 81.4 ± 9.6  64.1 ± 17.3 105.2 ± 9.5 95.8 ± 4.7 55.3 ± 17.9 94.4 ± 14.8 62.6 ± 11.8 29.1 ± 8.1 181 / 178 / -2 106 / 105 / -1 87 / 86 / -1 70
C21 MSH6 106 ± 10.8 88.1 ± 19.4 83.3 ± 18.4 105 ± 15 84.9 ± 18.7 45.9 ± 19.5 79.3 ± 19.7 72.6 ± 16.3 15.8 ± 1.3 180 / 180 / 0 105 / 105 / 0 86 / 86 / 0 270
C28 MLH1 17.2 ± 2.4 14.3 ± 3.1 13.3 ± 1.5 17.2 ± 3.4 14.1 ± 1.5 14 ± 1.6 18 ± 5.4 13.3 ± 1.2 13.6 ± 1.6 180 / 180 / 0 106 / 106 / 0 88 / 88 / 0 203
C26 PMS2 23.3 ± 6.5 19.3 ± 1.6 19.5 ± 3.9 27.1 ± 3.8 25.2 ± 7.4 21.1 ± 4.1 24.2 ± 3.6 21.4 ± 3.2 21.6 ± 3.9 179 / 179 / 0 105 / 105 / 0 86 / 86 / 0 139
C23 MSH6 98.2 ± 11.4 93.4 ± 8.4 91.5 ± 15.4 103.7 ± 17.3 90.9 ± 10.4 69.5 ± 15.9 86.3 ± 19.3 84.1 ± 17.7 28.9 ± 13.7 181 / 181 / 0 104 / 104 / 0 87 / 87 / 0 200
C29.1 PMS2 121.5 ± 17.2 99.4 ± 13.8 67.8 ± 13.7 122.1 ± 10.5 78.2 ± 20.6 32.1 ± 5.7 51.5 ± 8.6 39.1 ± 15.8 20.9 ± 2.4 181 / 180 / -1 101 / 100 / -1 86 / 86 / 0 66
C29.2  - 20.6 ± 5 15 ± 1.5 14.8 ± 1.2 16.7 ± 1.5 14.6 ± 1 14.3 ± 0.7 15.2 ± 1.8 14.3 ± 1.1 13.6 ± 0.9 180 / 180 / 0 101 / 101 / 0 86 / 86 / 0 105
C31  - 25 ± 13 13.4 ± 3 10 ± 1.6 13.7 ± 2.7 11.4 ± 1.6 9.5 ± 0.7 12.4 ± 1.3 10 ± 0.7 9.2 ± 0.6 180 / 180 / 0 105 / 105 / 0 86 / 86 / 0 70
C32  - 18.7 ± 1.4 16.8 ± 2.2 14.9 ± 1.1 18.8 ± 3.6 17.4 ± 3 15.3 ± 1.3 17.7 ± 1.4 16.4 ± 1.5 15.1 ± 1.1 180 / 180 / 0 106 / 106 / 0 87 / 87 / 0 131
C33  - 32 ± 15 21.2 ± 5.2 17 ± 5.5 24.7 ± 6.7 18.8 ± 5.6 17.1 ± 5.3 21.8 ± 5.2 19.1 ± 6.3 17.1 ± 6.1 180 / 180 / 0 105 / 105 / 0 87 / 87 / 0 80
C34.1  - 28.5 ± 5.9 17.4 ± 3.4 15.8 ± 2.7 22.9 ± 6.3 17.4 ± 2.3 15.2 ± 2 18.7 ± 5.1 14.5 ± 1.9 12.7 ± 1.2 181 / 181 / 0 105 / 105 / 0 87 / 87 / 0 150
C34.2  - 28.1 ± 2.6 21.5 ± 3.2 21.6 ± 3.9 24.3 ± 3.9 21.6 ± 3.9 21.7 ± 4.7 23 ± 4.9 21.9 ± 4.1 20.2 ± 4.8 180 / 180 / 0 105 / 105 / 0 86 / 86 / 0 140
C35  - 24.2 ± 9.1 15.3 ± 2.1 14.1 ± 2.4 22.5 ± 7.9 17 ± 3.4 15.2 ± 3.9 20.3 ± 3.7 18.2 ± 6.5 14.7 ± 2.5 180 / 180 / 0 106 / 106 / 0 87 / 87 / 0 144
C36  - 20.2 ± 6.7 18.2 ± 5.9 17.7 ± 7.3 21.4 ± 9.3 18.5 ± 7 18 ± 7.1 19.3 ± 7 17.6 ± 6.1 17.5 ± 6.3 180 / 180 / 0 105 / 105 / 0 87 / 87 / 0 175
C37  - 32.5 ± 11.2 18.7 ± 4.3 15.6 ± 2 24.4 ± 7.3 17.2 ± 3.4 15.2 ± 2.4 19.9 ± 5.1 15.8 ± 3.7 14.2 ± 3.1 180 / 180 / 0 106 / 106 / 0 87 / 87 / 0 135
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MMR wild-type individuals  
A3 APC ND ND ND ND ND ND ND ND ND 180 / 180 / 0 106 / 106 / 0 87 / 87 / 0 > 120
A2 APC ND ND ND ND ND ND ND ND ND 180 / 180 / 0 105 / 105 / 0 87 / 87 / 0 > 120
A1 APC 17.9 ± 2.2 16.4 ± 2.2 13.8 ± 2.1 16.3 ± 2.9 14.8 ± 2.3 14.7 ± 3.9 16.1 ± 1.7 14.7 ± 1.5 13.6 ± 2.9 180 / 180 / 0 105 / 105 / 0 86 / 86 / 0 > 120
A5 APC 15.6 ± 3.5 15.5 ± 3.3 14.6 ± 2.9 16.1 ± 3.6 15.5 ± 4 15.3 ± 2.5 15.3 ± 3.3 14.8 ± 3.5 13.6 ± 2.9 ND ND ND ND
A8 APC 18 ± 3.2 14.6 ± 1 13 ± 1 14 ± 1.6 13.6 ± 1 12 ± 0.9 15.1 ± 1.3 13.6 ± 0.9 14 ± 1.2 180 / 180 / 0 105 / 105 / 0 87 / 87 / 0 223
N1 NF1 ND ND ND ND ND ND ND ND ND 180 / 180 / 0 106 / 106 / 0 87 / 87 / 0 122
N3 NF1 20.8 ± 1.2 19.7 ± 1.3 18.3 ± 1.4 20.3 ± 1 19.8 ± 1.4 18.5 ± 1.2 20.5 ± 1.4 20 ± 1.2 18.4 ± 1 181 / 181 / 0 105 / 105 / 0 87 / 87 / 0 83
X1  - 25.3 ± 4.8 16.2 ± 3 13.4 ± 3.1 17.9 ± 3.6 14.4 ± 4.1 13.2 ± 3 18.6 ± 2.9 15 ± 2.3 13.6 ± 2.6 ND ND ND ND
X2  - 20.5 ± 4 18.3 ± 3.9 17.1 ± 4.5 19.2 ± 4.4 19.1 ± 4.7 18 ± 5.3 17.5 ± 2.8 16.6 ± 2.7 15.7 ± 2 180 / 180 / 0 105 / 105 / 0 87 / 87 / 0 135
X5  - 22.2 ± 3.9 17.5 ± 2.3 14.4 ± 1.9 20.1 ± 1.8 16.7 ± 1.1 15.4 ± 1.6 17.5 ± 2.4 16.8 ± 2.6 15.4 ± 2.3 180 / 180 / 0 106 / 106 / 0 86 / 86 / 0 138
X7  - 17.5 ± 2.3 16.3 ± 1.9 14.2 ± 2.1 16.2 ± 2.1 16 ± 2.8 15.1 ± 3.2 16.3 ± 2.1 15.6 ± 2.4 14.9 ± 2.2 180 / 180 / 0 105 / 105 / 0 86 / 86 / 0 142
X12  - 10 ± 1.6 8.9 ± 1 8.1 ± 0.7 9.4 ± 1.1 9.3 ± 0.8 9 ± 1 9.6 ± 0.8 9.3 ± 0.8 9 ± 1.4 180 / 180 / 0 105 / 105 / 0 87 / 87 / 0 173
X14  - 25 ± 2.4 21.4 ± 2 19.7 ± 0.7 24.1 ± 4.4 21.9 ± 3.2 21 ± 2.1 22.3 ± 3 21.1 ± 2.5 19.5 ± 2.1 ND ND ND ND
X13  - 17.7 ± 3.5 14.6 ± 2.6 13.6 ± 2.2 16.3 ± 2.8 15.1 ± 2.6 13.4 ± 2.3 15.4 ± 3.4 13.7 ± 2.4 13.3 ± 1.8 ND ND ND ND
X17  - 26 ± 5.4 24.2 ± 5.3 21.3 ± 5.7 37.8 ± 15.3 23.5 ± 6.7 18.4 ± 4.5 25 ± 8.4 19 ± 5.8 15.1 ± 2.5 181 / 181 / 0 105 / 105 / 0 85 / 85 / 0 237
Patients with Lynch syndrome  
C20.3 MSH6 ND ND ND ND ND ND ND ND ND 180 / 180 / 0 105 / 105 / 0 86 / 86 / 0 122
L13 MLH1 13.3 ± 1.8 12.8 ± 1.2 11.4 ± 1.2 13.1 ± 2.1 12.2 ± 1.4 11.5 ± 1.4 13.2 ± 1.8 12.3 ± 2 11.5 ± 1.9 180 / 180 / 0 106 / 106 / 0 87 / 87 / 0 > 120
L15 MLH1 17.2 ± 1.9 16.8 ± 1.7 15.4 ± 1.3 17.5 ± 1.3 17.3 ± 0.7 15.8 ± 0.6 16.9 ± 2.4 16.5 ± 2.2 15.3 ± 1.6 180 / 180 / 0 105 / 105 / 0 87 / 87 / 0 252
L20 MLH1 24.4 ± 11.5 15 ± 3.8 12.4 ± 1.9 22.5 ± 11.5 15.3 ± 3.9 12.9 ± 1.2 17.7 ± 1.8 16.4 ± 0.9 14.6 ± 0.9 180 / 180 / 0 106 / 106 / 0 86 / 86 / 0 126
L12 MSH2 45.8 ± 7 39 ± 10.6 20.6 ± 4.1 39.4 ± 9.5 24.2 ± 5.6 19.6 ± 4.3 28.1 ± 7.7 20.7 ± 3.2 18.9 ± 3.3 178 / 178 / 0 106 / 106 / 0 87 / 87 / 0 249
L14 MSH2 29.2 ± 5.5 23.3 ± 3.3 19.2 ± 3.4 28.1 ± 3.7 21.1 ± 2.2 19 ± 2.2 23.4 ± 2.6 21.1 ± 2.6 18.3 ± 3 180 / 180 / 0 105 / 105 / 0 87 / 87 / 0 > 120 
L16 MSH2 25.1 ± 6.9 16.8 ± 3 12.2 ± 2.3 18.4 ± 1.9 13.9 ± 2.5 11.7 ± 2 15.1 ± 3.5 12.3 ± 1.2 10.8 ± 1.1 180 / 180 / 0 106 / 106 / 0 86 / 86 / 0 207
L18 MSH2 33.4 ± 12.5 19 ± 2.3 13.9 ± 1.9 21.8 ± 2.1 17.3 ± 1.8 14.8 ± 2.1 17.5 ± 2.9 15 ± 1.7 13.2 ± 1 179 / 179 / 0 105 / 105 / 0 85 / 85 / 0 214
L17 MSH6 53.2 ± 11.5 32.2 ± 5.8 24.2 ± 6.9 40.9 ± 7.3 28.6 ± 1.9 20.8 ± 5.8 30.6 ± 4.8 25.4 ± 5.7 20.4 ± 8 179 / 179 / 0 105 / 105 / 0 86 / 86 / 0 304
L19 MSH6 58 ± 16.8 42.6 ± 19 22.6 ± 9.7 49.8 ± 17 25.6 ± 6.9 14 ± 3.2 38.8 ± 10.6 26.2 ± 13.8 12.4 ± 2 179 / 179 / 0 106 / 106 / 0 85 / 85 / 0 203
C13.2 MSH6 47.2 ± 12.2 36.2 ± 9.9 24.9 ± 8.5 41.5 ± 16.4 28 ± 8 20.5 ± 2.8 34.6 ± 10.3 21.9 ± 4.3 19 ± 2.3 180 / 180 / 0 105 / 105 / 0 87 / 87 / 0 100
C09.2 PMS2 54.7 ± 16.9 20.9 ± 6.7 15.3 ± 2.2 30.2 ± 12.6 17.9 ± 5.1 15.3 ± 3.3 21 ± 5.2 15.4 ± 2.3 14.2 ± 3.2 181 / 181 / 0 105 / 105 / 0 87 / 87 / 0 120
L42 PMS2 28.4 ± 11.8 17.7 ± 3.5 15.4 ± 2.7 23.1 ± 6.5 16.6 ± 3.1 15.6 ± 2.7 17.5 ± 3.7 16.4 ± 3.3 15.2 ± 2.7 ND ND ND ND
L4 MLH1 34.9 ± 16.2 19.4 ± 3.2 17.8 ± 2.7 26.1 ± 5.3 20.1 ± 3 16.1 ± 2.8 25.1 ± 11.5 18.7 ± 3.8 12.9 ± 1 ND ND ND ND
L5 MSH2 33.1 ± 6.5 26 ± 4.8 20.4 ± 0.6 32.1 ± 5.5 25.8 ± 6.4 17.1 ± 0.9 36.5 ± 14.4 26.1 ± 5.5 19.5 ± 1.7 ND ND ND ND
L7 MSH2 56.3 ± 16 27 ± 9.5 25 ± 7.8 51.4 ± 19.7 27.5 ± 13.6 18.8 ± 5.4 28.3 ± 11.4 18.6 ± 5.4 15.5 ± 3.6 ND ND ND ND
L3 MSH2 53.3 ± 18.3 26.6 ± 8.8 19.2 ± 4.1 39.4 ± 10.2 23.3 ± 3.4 16.9 ± 4.1 26.6 ± 5.8 17.9 ± 4.8 14.9 ± 3.7 ND ND ND ND
L34 MSH6 59.9 ± 15.3 43.3 ± 6.1 17.6 ± 3.2 53.9 ± 9.5 25.9 ± 9 11.6 ± 0.4 42.1 ± 9.9 16 ± 3.1 11.6 ± 0.7 ND ND ND ND
L33 MSH2 26.9 ± 9 19.6 ± 6.4 19.2 ± 3.6 30 ± 13.1 19.8 ± 4.4 17.5 ± 2.7 21 ± 4 20.1 ± 4.7 16.6 ± 2 ND ND ND ND
L29 MSH2 56 ± 9.4 30.1 ± 5 21.6 ± 3.1 34.9 ± 7.9 23.8 ± 2.1 20 ± 2 29.6 ± 6 21.8 ± 2.1 21.1 ± 1.5 ND ND ND ND
L24 MSH2 21.9 ± 4.6 17.3 ± 2.7 16.4 ± 3.7 18.5 ± 3.3 16.7 ± 2.8 15.7 ± 3 17.8 ± 2.8 16.9 ± 2.7 15 ± 1.7 ND ND ND ND
L23 MSH2 58.7 ± 13 31.4 ± 10.6 21.1 ± 4.3 43.5 ± 15.9 25.7 ± 5.8 19.8 ± 2.6 29.5 ± 8.1 21.9 ± 4.1 17 ± 1.1 ND ND ND ND
L40 PMS2 67.5 ± 9 27 ± 7.6 19.8 ± 3.8 36.4 ± 8.7 19.4 ± 2.9 17.5 ± 2.9 21 ± 5.7 16.9 ± 3.6 14.4 ± 0.6 ND ND ND ND
L41 PMS2 61.8 ± 7 24.2 ± 8.7 17.4 ± 3.7 31.1 ± 13.6 17.9 ± 4.2 13.8 ± 2.3 28.2 ± 12.1 14.9 ± 1.8 11.5 ± 2.3 ND ND ND ND
L47 MSH6 70.9 ± 12.6 47.6 ± 15.5 30.3 ± 12.6 60.3 ± 15.8 34.4 ± 10.1 22.6 ± 5.5 39.2 ± 17.6 26 ± 8.3 17 ± 1.3 ND ND ND ND
L21 MSH2 19.4 ± 7.6 12 ± 2.7 10.9 ± 1.2 13.2 ± 2.1 11.7 ± 0.9 11 ± 0.7 12.9 ± 2.2 11 ± 1 11.1 ± 0.7 ND ND ND ND
L27 MLH1 12 ± 4.8 10.8 ± 4.5 10.1 ± 4.2 15.9 ± 6.4 14 ± 5 15.2 ± 5.5 9.8 ± 1.7 8.2 ± 1.7 8.8 ± 0.6 ND ND ND ND
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L50 MSH6 79.6 ± 14.5 58.2 ± 12.9 27.7 ± 5.1 72.9 ± 14.8 37.9 ± 10.6 18.7 ± 3.8 52.2 ± 18.4 24.6 ± 8.5 16.4 ± 3.7 ND ND ND ND
L52 MSH6 68.5 ± 8.4 49.9 ± 12.4 31.4 ± 7 54.4 ± 10 38 ± 8.8 21.6 ± 3.7 41.2 ± 10.8 26.1 ± 6.8 17.5 ± 1.6 ND ND ND ND
L53 MSH6 92.3 ± 9.5 72.5 ± 9.2 36 ± 13.5 83 ± 12.3 60.4 ± 10.1 23.3 ± 7.4 68 ± 10.1 34.7 ± 11.6 17.5 ± 5.6 ND ND ND ND
L54 MSH6 82 ± 17.2 61.2 ± 14.2 24.5 ± 13.2 67.5 ± 12.1 32 ± 9.8 13.9 ± 3.8 31.9 ± 2.5 18.1 ± 5 11.7 ± 2 ND ND ND ND
L55 MSH6 55.8 ± 16 39.5 ± 14.4 23.3 ± 2.8 44.2 ± 11.8 37.8 ± 14.8 20.6 ± 1.3 35.7 ± 8.7 31.5 ± 12.9 35 ± 17.2 ND ND ND ND
L56 MLH1 21.7 ± 7.9 15.7 ± 2.7 12.5 ± 3.2 15.9 ± 2 15 ± 1.5 14 ± 0.5 16 ± 1.9 13.3 ± 1.4 12.9 ± 0.6 ND ND ND ND
L28 MLH1 9.5 ± 0.9 9 ± 0.5 8.9 ± 1 10.3 ± 1 9.3 ± 1.1 9.6 ± 1.2 10 ± 0.9  9.3 ± 1.1 9.8 ± 1.2 ND ND ND ND
L43 MLH1 13.7 ± 2.6 11.8 ± 1.5 11.3 ± 1.5 13 ± 1.5 12.5 ± 1.6 11.9 ± 1.5 12.5 ± 1.3 12.2 ± 1.3 11.8 ± 1.7 ND ND ND ND
L44 MLH1 19.3 ± 15.6 10.6 ± 3.2 9.9 ± 2.1 12.1 ± 3.6 10.8 ± 2.3 10.3 ± 1.8 11.7 ± 2.8 10.6 ± 2 11.1 ± 2.9 ND ND ND ND
L45 MLH1 18.3 ± 5.2 15.4 ± 6.7 10.4 ± 3.5 17.2 ± 6.7 12.1 ± 3.7 10.5 ± 3.1 12.4 ± 3.1 11.4 ± 3.9 10.6 ± 2.8 ND ND ND ND
L46 MLH1 9.2 ± 2.8 8.5 ± 2.1 8.2 ± 1.7 9.5 ± 2.3 9.2 ± 1.8 8.9 ± 1.8 9.7 ± 2.5 9.9 ± 3.3 9.3 ± 1.6 ND ND ND ND
L48 MSH6 70.2 ± 14.7 31.7 ± 7.9 21.4 ± 2 44.3 ± 14.9 21.7 ± 2.8 17.5 ± 2.6 27.8 ± 7.3 19.6 ± 4.8 14.7 ± 1.9 ND ND ND ND
L49 MSH6 22.4 ± 1.8 21.2 ± 2 24.1 ± 10.4 21.3 ± 1.7 21.7 ± 2.2 20.1 ± 1.4 21.6 ± 1 21.5 ± 1.2 20.6 ± 2 ND ND ND ND
L51 MSH6 54.8 ± 11 33.7 ± 9.3 22.4 ± 4.3 43.9 ± 14.8 25.5 ± 6.1 21.6 ± 5.2 34.5 ± 10 22.3 ± 5.4 19.6 ± 5.2 ND ND ND ND
 
Supplementary Table 2. Raw data relative to methylation tolerance and evMSI tests in all patients analyzed in the study 
 
a For each MNNG condition, mean cell survival (%) ± standard deviation are indicated. 
b The size (in base pairs) of each marker is indicated in peripheral blood lymphocytes, in immortalized lymphocytes, along with the difference between the two 
(i.e. deletion size) at the indicated culture time (in days). For the cell lines displaying a shift in allele size, the shortest culture time showing evMSI is indicated, 
whereas for the cell lines displaying stable allele profiles, the longest culture time is indicated. Culture time was calculated from the day of lymphoblast 
immortalization. Since peripheral blood lymphocytes were not available for CMMRD patient C01.2, comparison of the allele size was performed with primary 
blood lymphocytes from the father.  
 
ND, not done; X, unknown. 
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CMMRD patients
C01.1 PMS2 0.58 ± 0.012 0.37 ± 0.037 0.10 ± 0.006 positive
C02 PMS2 NA NA NA NI
C04 PMS2 0.85 ± 0.007 0.48 ± 0.008 NA positive
C05 PMS2 NA 0.21 ± 0.071 0.77 ± 0.086 positive
C06 PMS2 0.40 ± 0.040 0.25 ± 0.015 0.23 ± 0.012 positive
C07 PMS2 0.45 ± 0.016 0.14 ± 0.005 0.13 ± 0.009 positive
C08 PMS2 0.45 ± 0.013 0.26 ± 0.021 0.08 ± 0.009 positive
C09.1 PMS2 NA 0.14 ± 0.015 0.11 ± 0.007 positive
C10 PMS2 0.58 ± 0.034 NA 0.33 ± 0.023 positive
C12 MSH6 NA 0.00 ± 0.000 0.04 ± 0.002 negative
C13.1 MSH6 0.04 ± 0.034 0.03 ± 0.023 0.02 ± 0.014 negative
C14 MSH6 0.12 ± 0.005 NA NA NI
C15 MLH1 0.94 ± 0.012 NA 0.29 ± 0.011 positive
C03.1 PMS2 0.44 ± 0.016 0.35 ± 0.023 0.17 ± 0.016 positive
C03.2 PMS2 0.36 ± 0.018 0.00 ± 0.000 0.28 ± 0.004 positive
C11 PMS2 0.38 ± 0.018 0.19 ± 0.007 0.14 ± 0.029 positive
C16 MLH1 0.28 ± 0.025 0.09 ± 0.006 NA NI
C17 MSH2 0.21 ± 0.016 0.16 ± 0.006 0.07 ± 0.008 positive
Patients at-risk for CMMRD 
C20.1 MSH6 0.09 ± 0.005 0.03 ± 0.002 NA negative
C20.2 MSH6 0.09 ± 0.005 0.04 ± 0.005 NA negative
C18 PMS2 NA 0.05 ± 0.003 0.04 ± 0.002 negative
C27 MLH1 0.08 ± 0.001 0.00 ± 0.000 0.02 ± 0.001 negative
C25 PMS2 0.06 ± 0.004 0.03 ± 0.001 0.01 ± 0.013 negative
C22 MSH6 0.09 ± 0.009 0.03 ± 0.027 0.04 ± 0.005 negative
C24 MSH2 0.07 ± 0.002 0.03 ± 0.002 0.01 ± 0.014 negative
C30 MSH2 0.05 ± 0.002 NA 0.04 ± 0.010 negative
C19 PMS2 0.24 ± 0.015 0.02 ± 0.028 NA NI
C21 MSH6 0.02 ± 0.034 0.00 ± 0.000 0.02 ± 0.017 negative
C28 MLH1 0.08 ± 0.002 0.01 ± 0.018 0.04 ± 0.006 negative
C26 PMS2 NA 0.00 ± 0.000 0.02 ± 0.002 negative
C23 MSH6 0.09 ± 0.006 0.06 ± 0.007 0.04 ± 0.005 negative
C29.1 PMS2 0.41 ± 0.049 0.18 ± 0.021 0.29 ± 0.008 positive
C29.2  - 0.02 ± 0.041 0.01 ± 0.019 0.02 ± 0.001 negative
C31  - 0.08 ± 0.003 0.00 ± 0.000 0.04 ± 0.001 negative
C32  - 0.07 ± 0.005 0.03 ± 0.003 NA negative
C33  - NA NA NA NI
C34.1  - 0.05 ± 0.043 0.03 ± 0.001 0.00 ± 0.000 negative
C34.2  - 0.05 ± 0.027 0.00 ± 0.000 0.03 ± 0.046 negative
C35  - 0.00 ± 0.000 0.00 ± 0.000 0.02 ± 0.015 negative
C36  - 0.05 ± 0.046 0.01 ± 0.016 NA negative
C37  - 0.06 ± 0.011 0.01 ± 0.017 NA negative
gMSI ratio
Mutated 
gene 
Patient
Supplementary Table 3. Data set relative to gMSI testing in patients analyzed in the study 
 
Test result is positive (i.e. abnormal) when the gMSI ratios of at least 2 markers are above the cut-off 
value, and negative (i.e. normal)  when the gMSI ratios of at least 2 markers are below the cut-off 
value. 
NI, not interpretable; NA, not applicable because of heterozygous markers with alleles closer than 6 
base pairs. 
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PPV % (95% CI)
Patients and controls with available data n=56
Sequencing of MMR genes 93.6 (77.9 - 99.8)
ev MSI and methylation tolerance 80.5 (53.9 - 99.0)
Patients and controls with available data n=40
Sequencing of MMR genes 92.1 (72.8 - 99.9)
ev MSI and methylation tolerance 82.6 (55.3 - 99.2)
gMSI test 90.8 (69.0 - 99.8)
Supplementary table 4. Estimate of the sensitivity, specificity, negative and positive predictive values of the different tests for CMMRD diagnosis.
Ev MSI and methylation tolerance assays were first compared to the standard diagnostic method, i. e . sequencing of the MMR genes (56 patients with
available data), then the 3 tests under investigation were further compared (40 patients with available data).
CI, confidence interval; NPV, negative predictive value; PPV; positive predictive value. 
68.7 (42.6 - 91.0) 96.2 (86.8 - 99.9) 84.4 (67.5 - 96.4)
75.5 (49.3 - 96.5) 96.4 (87.0 - 99.9) 87.3 (70.2 - 98.5)
93.3 (76.7 - 99.8) 89.3 (72.5 - 99.5) 96.0 (85.6 - 99.9)
NPV % (95% CI)sensitivity % (95% CI) specificity % (95% CI)
80.1 (54.1 - 99.0)
94.2 (79.4 - 99.9)
97.6 (91.2 - 99.9)
90.1 (76.1 - 99.5)
91.2 (76.6 - 99.6)
97.2 (89.8 - 99.9)
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